MTHFR AND ММР-12 GENES MUTATIONS EFFECT ON THE ACTIVITY OF PROOXIDANT AND PROFIBROTIC AGENTS AND HOMOCYSTEINE LEVELS IN PATIENTS WITH BREAST CANCER

Summary. This thesis is devoted to the studying of the gene methylenetetrahydrofolate reductase (MTHFR) and matrix metalloproteinase (MMP-12) mutations in inflammation mediators activation, prooxidant and profibrotic agents in patients with breast cancer. It was found that the prevalence of C677T MTHFR mutations in patients with ВС (breast cancer) is higher than in the general population. In patients with heterozygous CT and homozygous TT allele of MTHFR gene significantly increases homocysteine level, interleykin-6, CRP (C-reactive protein), TGF-β1(transforming growth factor), free oxyproline and markers of oxidative stress. This increases the risk of thromboembolism, pulmonary and liver fibrosis, especially after chemo-radiation therapy. Polymorphisms in MMP-12 gene is not associated with systemic changes and hyperhomocysteinemia and systemic changes of TGF-β1 content, interleykin-6, CRP, oxidative stress markers in serum, but in combination with the S677T MTHFR mutations, increases the negative impact of the latter.